TransMedics Ebit Per Revenue from 2010 to 2024

TMDX Stock  USD 86.71  0.40  0.46%   
TransMedics Ebit Per Revenue yearly trend continues to be fairly stable with very little volatility. Ebit Per Revenue will likely drop to -0.12 in 2024. During the period from 2010 to 2024, TransMedics Ebit Per Revenue regression line of annual values had significance of  0.15 and arithmetic mean of (1.29). View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
(0.12)
Current Value
(0.12)
Quarterly Volatility
0.90841254
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TransMedics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TransMedics' main balance sheet or income statement drivers, such as Interest Expense of 11.3 M, Selling General Administrative of 125.5 M or Research Development of 22.2 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 19.64. TransMedics financial statements analysis is a perfect complement when working with TransMedics Valuation or Volatility modules.
  
Check out the analysis of TransMedics Correlation against competitors.

Latest TransMedics' Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of TransMedics Group over the last few years. It is TransMedics' Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TransMedics' overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Slightly volatile
   Ebit Per Revenue   
       Timeline  

TransMedics Ebit Per Revenue Regression Statistics

Arithmetic Mean(1.29)
Coefficient Of Variation(70.33)
Mean Deviation0.54
Median(1.25)
Standard Deviation0.91
Sample Variance0.83
Range3.5832
R-Value0.39
Mean Square Error0.75
R-Squared0.16
Significance0.15
Slope0.08
Total Sum of Squares11.55

TransMedics Ebit Per Revenue History

2023 -0.12
2022 -0.34
2021 -1.3
2019 -1.03
2018 -1.55
2017 -2.66
2016 -3.7

About TransMedics Financial Statements

TransMedics investors use historical fundamental indicators, such as TransMedics' Ebit Per Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TransMedics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Ebit Per Revenue(0.12)(0.12)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.